4 reports

  • SEP 12, 2017: ZAFGEN INITIATES PHASE 2 CLINICAL TRIAL FOR ZGN-1061 IN PATIENTS WITH TYPE 2 DIABETES
  • SEP 20, 2016: ZAFGEN INITIATES MULTIPLE ASCENDING DOSE COHORTS IN PHASE 1 CLINICAL TRIAL OF ZGN-1061

Patients in the clinical trial experienced mean weight loss of up to approximately one pound per week.

  • Clinical Trial
  • China
  • World
  • Product Initiative
  • Zafgen, Inc.
  • Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
  • Mar 09, 2017: Zafgen Provides Update on ZGN-1061

A Phase ## clinical trial for ZGN-## is expected to begin in the fourth quarter of 2018.

  • Clinical Trial
  • Healthcare
  • United States
  • Company
  • Zafgen, Inc.
  • SEP 12, 2017: ZAFGEN INITIATES PHASE 2 CLINICAL TRIAL FOR ZGN-1061 IN PATIENTS WITH TYPE 2 DIABETES
  • MAY 04, 2017: ZAFGEN ANNOUNCES POSITIVE TOP LINE PHASE 1 DATA FOR ZGN-1061, A SECOND GENERATION METAP2 INHIBITOR

ZAFGEN ALSO PRESENTED FINDINGS FROM THE COMPANY' S PHASE ## CLINICAL TRIAL OF ZGN-##.

  • Clinical Trial
  • United States
  • World
  • Product Initiative
  • Zafgen, Inc.

In the clinical trial, there were a total of nine serious adverse events (SAEs) identified in eight patients, one in the ##. ## mg group, six in the ##. ## mg group, and two in the placebo group.

  • Clinical Trial
  • United States
  • World
  • Product Initiative
  • Zafgen, Inc.